JP2022509354A - 肺を処置するための組成物および方法 - Google Patents

肺を処置するための組成物および方法 Download PDF

Info

Publication number
JP2022509354A
JP2022509354A JP2021547650A JP2021547650A JP2022509354A JP 2022509354 A JP2022509354 A JP 2022509354A JP 2021547650 A JP2021547650 A JP 2021547650A JP 2021547650 A JP2021547650 A JP 2021547650A JP 2022509354 A JP2022509354 A JP 2022509354A
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
nicotine
glutathione
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021547650A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022509354A5 (https=
Inventor
ジョージ エドワード ホーグ，
ジョン サレルノ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HOAG, George, Edward
Original Assignee
HOAG, George, Edward
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HOAG, George, Edward filed Critical HOAG, George, Edward
Publication of JP2022509354A publication Critical patent/JP2022509354A/ja
Publication of JP2022509354A5 publication Critical patent/JP2022509354A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021547650A 2018-10-23 2019-10-23 肺を処置するための組成物および方法 Ceased JP2022509354A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862749446P 2018-10-23 2018-10-23
US62/749,446 2018-10-23
PCT/US2019/057722 WO2020086759A2 (en) 2018-10-23 2019-10-23 Composition and method for treating the lungs

Publications (2)

Publication Number Publication Date
JP2022509354A true JP2022509354A (ja) 2022-01-20
JP2022509354A5 JP2022509354A5 (https=) 2022-10-31

Family

ID=70331261

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021547650A Ceased JP2022509354A (ja) 2018-10-23 2019-10-23 肺を処置するための組成物および方法

Country Status (13)

Country Link
US (1) US20220000966A1 (https=)
EP (1) EP3869985A4 (https=)
JP (1) JP2022509354A (https=)
KR (1) KR20210119376A (https=)
CN (2) CN113365513B (https=)
AU (1) AU2019365216A1 (https=)
BR (1) BR112021007692A2 (https=)
CA (1) CA3117213A1 (https=)
IL (1) IL282600A (https=)
MX (1) MX2021004692A (https=)
SG (1) SG11202104158SA (https=)
WO (1) WO2020086759A2 (https=)
ZA (1) ZA202103404B (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023210481A1 (ja) * 2022-04-28 2023-11-02 学校法人近畿大学 カリオフィレン含有組成物
KR102745803B1 (ko) * 2023-07-28 2024-12-24 주식회사 배젠 호두 분쇄 추출물을 이용한 폐질환 치료용 조성물 및 이의 치료용 용도
JP7649095B1 (ja) * 2024-10-07 2025-03-19 日本たばこ産業株式会社 自己乳化組成物
JP2025533322A (ja) * 2022-11-24 2025-10-03 長風薬業股▲ふん▼有限公司 （－）－エピガロカテキンガレート化合物の使用

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230117644A (ko) 2016-11-17 2023-08-08 레노비온, 아이엔씨. 글루타티온 조성물에 의한 호흡기 질환 및 감염 치료
ES3008699T3 (en) 2017-11-17 2025-03-24 Renovion Inc Stable ascorbic acid compositions and methods of using the same
WO2021146662A1 (en) * 2020-01-17 2021-07-22 Muhammed Majeed Therapeutic compositions and methods for pulmonary fibrosis
EP4146188A4 (en) * 2020-05-08 2024-06-19 Theaprin Pharmaceuticals Inc. COCRYSTALLINE ANTIOXIDANTS OF PROTOCATECHIC ACID WITH L-THEANINE FOR THE TREATMENT OF OXIDATIVE STRESS AND INFLAMMATORY DISEASES
WO2021245655A1 (en) * 2020-05-31 2021-12-09 Roxx Labs Ltd. Compositions comprising cannabinoids and volatile anesthetics for inhalation and anti-viral uses thereof
EP4167989A4 (en) * 2020-06-19 2024-07-03 Peter Hofleitner COMPOSITION FOR THE TREATMENT OF VIRUS INFECTIONS
EP3949964A1 (en) * 2020-08-06 2022-02-09 Nuvamid SA Combination of nicotinamide mononucleotide derivatives and other therapeutic agents for use in the treatment of viral infections
WO2022029275A1 (en) * 2020-08-06 2022-02-10 Nuvamid Sa Combination of nicotinamide mononucleotide derivatives and other therapeutic agents for use in the treatment of coronavirus infections and covid-19
WO2023285984A1 (en) * 2021-07-14 2023-01-19 Redox-Co S.R.L. Glutahtione c4 against airway affections
IL313997A (en) 2022-01-04 2024-08-01 Renovion Inc Aqueous solution including glutathione salt
WO2023233183A1 (en) * 2022-06-01 2023-12-07 VOLPI, Simone Pharmaceutical compositions for treating neurological diseases
CN117205319B (zh) * 2022-06-02 2024-09-03 中国人民解放军军事科学院军事医学研究院 Hc030031在制备预防或治疗百草枯中毒引起的肺损伤的药物中的应用
CN114903995B (zh) * 2022-06-02 2023-07-28 中国人民解放军军事科学院军事医学研究院 Trpa1离子通道作为药物靶点在酰胺类除草剂中毒中的应用
WO2024016019A1 (en) * 2022-07-15 2024-01-18 Renovion, Inc. Compositions and methods for treatment of subjects suffering from a sars-cov-2 infection
WO2024025525A1 (en) * 2022-07-27 2024-02-01 Medterra Pharma Llc Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders
CN117679423A (zh) * 2022-09-05 2024-03-12 立生医药(苏州)有限公司 预防或治疗呼吸系统疾病的吸入用药物组合物
CN117981896A (zh) * 2022-10-28 2024-05-07 思摩尔国际控股有限公司 复合烟碱盐、复合烟碱盐调配物及其制备方法和应用
CN115813011A (zh) * 2022-12-30 2023-03-21 东莞市吉纯生物技术有限公司 一种具有茶氨酸的雾化液的制备方法与应用
WO2024161313A1 (en) * 2023-01-31 2024-08-08 Rai Strategic Holdings, Inc. Stabilized aerosol precursor formulations
CN115998758B (zh) * 2023-03-01 2024-04-19 中国药科大学 甲钴胺及药物组合物在制备用于治疗肝衰竭药物中的应用
CN121001726A (zh) * 2023-03-01 2025-11-21 里格尔药品股份有限公司 Syk抑制剂用于治疗化学或辐射诱导的肺损伤的用途
TWI872951B (zh) * 2024-02-19 2025-02-11 高雄醫學大學 用於治療、預防或減輕肺功能損傷之類黃酮藥物
WO2025231041A1 (en) * 2024-04-30 2025-11-06 Renovion, Inc. Methods for reducing symptoms in subjects suffering from bronchiectasis and other pulmonary diseases
CN119015390B (zh) * 2024-10-29 2025-03-28 江西中医药大学附属医院 一种治疗慢性咳嗽的中药脐贴及其制备方法
CN119385331A (zh) * 2024-12-05 2025-02-07 河南中烟工业有限责任公司 一种功能型特色再造烟叶的制备及应用
CN120123897B (zh) * 2025-03-11 2026-04-03 广东海洋大学 一种育珠贝生长环境监测方法及系统
CN120284942B (zh) * 2025-04-22 2025-12-16 西南医科大学附属中医医院 桑辛素类化合物在制备治疗慢性肾脏病的药物中的用途
CN121775153A (zh) * 2026-03-05 2026-04-03 四川大学华西医院 多酚/胺复合物、肺靶向递送系统及其构建方法及应用

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05501263A (ja) * 1989-11-24 1993-03-11 アメリカ合衆国 グルタチオンのエーロゾル製剤
JP2005504001A (ja) * 2001-02-14 2005-02-10 デューク・ユニバーシティ Ｇｓｎｏの充足を起こすガス状薬剤による肺疾患の処置
JP2007511539A (ja) * 2003-11-14 2007-05-10 バクスター・インターナショナル・インコーポレイテッド α１−抗トリプシン組成物およびこのような組成物を用いた処置方法
US20090169487A1 (en) * 2007-12-28 2009-07-02 Hedayat Kamyar Malek Essential Oil Diffusion
JP2009537569A (ja) * 2006-05-18 2009-10-29 ティカ レーケメデル アーベー 気管支拡張を誘発するためのβ２アゴニストの送達のための方法およびそれを使用するための製剤
JP2010504171A (ja) * 2006-09-20 2010-02-12 ネクスト セーフティ インコーポレイテッド 吸入を通した薬物供給の方法およびシステム
JP2011001383A (ja) * 2002-04-25 2011-01-06 Scripps Research Inst 肺病態の治療および予防
JP2013194036A (ja) * 2012-03-22 2013-09-30 Kobayashi Pharmaceutical Co Ltd 医薬組成物
JP2014521634A (ja) * 2011-07-25 2014-08-28 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１アンタゴニスト及びステロイドを含む医薬組成物
JP2016503390A (ja) * 2012-10-23 2016-02-04 シプラ・リミテッド 医薬組成物
US20170273914A1 (en) * 2014-08-25 2017-09-28 Janing Holding Aps Device with compositions for delivery to the lungs, the oral mucosa and the brain
JP2018529736A (ja) * 2015-09-30 2018-10-11 ホーグ、ジョージ、エドワードＨＯＡＧ， Ｇｅｏｒｇｅ， Ｅｄｗａｒｄ 局所鎮痛性疼痛緩和製剤、その製造及び使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69124223T2 (de) * 1990-02-05 1997-04-30 Lifescience Corp Vitamine und mineralien enthaltende nahrungszusätze
PE20140234A1 (es) * 2010-12-20 2014-03-08 Glenmark Phamaceuticals S A Compuestos de 2-amino-4-ariltiazol como antagonistas de trpa1
CA2836856A1 (en) * 2011-06-13 2012-12-20 Glenmark Pharmaceuticals, S.A. Treatment of respiratory disorders using trpa1 antagonists
HUE052275T2 (hu) * 2013-01-28 2021-04-28 Incozen Therapeutics Pvt Ltd Eljárások autoimmun, légzõszervi és gyulladásos rendellenességek kezelésére roflumilaszt N-oxid inhalálásával
TWI676626B (zh) * 2014-04-23 2019-11-11 美商美國禮來大藥廠 抑制瞬時受體電位ａ１離子通道
US9867779B2 (en) * 2015-03-26 2018-01-16 Patheon Softgels Inc. Liquisoft capsules

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05501263A (ja) * 1989-11-24 1993-03-11 アメリカ合衆国 グルタチオンのエーロゾル製剤
JP2005504001A (ja) * 2001-02-14 2005-02-10 デューク・ユニバーシティ Ｇｓｎｏの充足を起こすガス状薬剤による肺疾患の処置
JP2011001383A (ja) * 2002-04-25 2011-01-06 Scripps Research Inst 肺病態の治療および予防
JP2007511539A (ja) * 2003-11-14 2007-05-10 バクスター・インターナショナル・インコーポレイテッド α１−抗トリプシン組成物およびこのような組成物を用いた処置方法
JP2009537569A (ja) * 2006-05-18 2009-10-29 ティカ レーケメデル アーベー 気管支拡張を誘発するためのβ２アゴニストの送達のための方法およびそれを使用するための製剤
JP2010504171A (ja) * 2006-09-20 2010-02-12 ネクスト セーフティ インコーポレイテッド 吸入を通した薬物供給の方法およびシステム
US20090169487A1 (en) * 2007-12-28 2009-07-02 Hedayat Kamyar Malek Essential Oil Diffusion
JP2014521634A (ja) * 2011-07-25 2014-08-28 グレンマーク ファーマシューティカルズ， エセ．アー． Ｔｒｐａ１アンタゴニスト及びステロイドを含む医薬組成物
JP2013194036A (ja) * 2012-03-22 2013-09-30 Kobayashi Pharmaceutical Co Ltd 医薬組成物
JP2016503390A (ja) * 2012-10-23 2016-02-04 シプラ・リミテッド 医薬組成物
US20170273914A1 (en) * 2014-08-25 2017-09-28 Janing Holding Aps Device with compositions for delivery to the lungs, the oral mucosa and the brain
JP2018529736A (ja) * 2015-09-30 2018-10-11 ホーグ、ジョージ、エドワードＨＯＡＧ， Ｇｅｏｒｇｅ， Ｅｄｗａｒｄ 局所鎮痛性疼痛緩和製剤、その製造及び使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RESPIRATORY RESEARCH, vol. 10, JPN6023038725, 2009, pages 1 - 7, ISSN: 0005489176 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023210481A1 (ja) * 2022-04-28 2023-11-02 学校法人近畿大学 カリオフィレン含有組成物
JP2025533322A (ja) * 2022-11-24 2025-10-03 長風薬業股▲ふん▼有限公司 （－）－エピガロカテキンガレート化合物の使用
KR102745803B1 (ko) * 2023-07-28 2024-12-24 주식회사 배젠 호두 분쇄 추출물을 이용한 폐질환 치료용 조성물 및 이의 치료용 용도
JP7649095B1 (ja) * 2024-10-07 2025-03-19 日本たばこ産業株式会社 自己乳化組成物

Also Published As

Publication number Publication date
AU2019365216A1 (en) 2021-06-10
ZA202103404B (en) 2023-11-29
WO2020086759A2 (en) 2020-04-30
CN113365513B (zh) 2025-04-25
MX2021004692A (es) 2021-06-23
US20220000966A1 (en) 2022-01-06
WO2020086759A9 (en) 2020-06-18
SG11202104158SA (en) 2021-05-28
CN113365513A (zh) 2021-09-07
KR20210119376A (ko) 2021-10-05
EP3869985A2 (en) 2021-09-01
IL282600A (en) 2021-06-30
BR112021007692A2 (pt) 2021-08-10
CN120285204A (zh) 2025-07-11
WO2020086759A3 (en) 2020-05-22
EP3869985A4 (en) 2022-07-27
CA3117213A1 (en) 2020-04-30

Similar Documents

Publication Publication Date Title
CN113365513B (zh) 用于治疗肺的组合物和方法
US20230355571A1 (en) Method for treating viral and bacterial infection through inhalation therapy
Rabinoff et al. Pharmacological and chemical effects of cigarette additives
JP2022509354A5 (https=)
CA2359813C (en) Nicotine mucosal spray
US20020117180A1 (en) Glutathione, green tea, grape seed extract to neutralize tobacco free radicals
US11311586B2 (en) Plant stem cell product treatments
US20180271826A1 (en) Dry powders of cannabinoids and methods for preparing dry powders
Schichlein et al. Protective effects of inhaled antioxidants against air pollution-induced pathological responses
CN102316850A (zh) 一种用于戒烟的口腔吸收尼古丁组合物
Karlsson et al. Hyperresponsiveness to tussive stimuli in cigarette smoke‐exposed guinea‐pigs: a role for capsaicin‐sensitive, calcitonin gene‐related peptide‐containing nerves
CN110353298A (zh) 电子烟液
US20150038576A1 (en) Compositions and their use for smoking cessation and other treatments
Jayeshkumar et al. Nebulization therapy for lung cancer
Patel et al. A brief review on effect of oxidative stress on various diseases including a lung diseases
US20220080020A1 (en) Compositions and methods for reducing the transmissivity of illnesses using an oral delivery system
Cox The E-Liquid Flavorings Cinnamaldehyde, Vanillin, and Ethyl Vanillin Induce Cellular Stress Responses in Human Proximal Tubule (HK-2) Epithelial Cells
Witten et al. Chronic sidestream cigarette smoke exposure causes lung injury in rabbits
WO2024025525A1 (en) Cannabinoid compositions and methods of using for the treatment of non-eosinophilic inflammation and inflammatory disorders
CN111050762A (zh) 减轻肺部炎症的方法
Dhaduk et al. Marijuana: an in-depth look at its use, cause, and effects in medical applications.
Karlage et al. Inhalation of an ethanol-based zileuton formulation provides a reduction of pulmonary adenomas in the A/J mouse model
Koizumi et al. Smoking accelerates absorption of inhaled neutrophil elastase inhibitor FK706
Ferkol Cannabis and electronic cigarette use in youths
Rathod et al. REVIEW ON POLYHERBAL COUGH POWDER

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230920

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240321

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240530

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250522

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250908

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20251219